D. Stuart

发表

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2008, Journal of medicinal chemistry.

A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1

D. Stuart, T. Allen, G. Kao, 2000, Cancer Gene Therapy.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

W. Sellers, R. Dummer, Fernando Salangsang, 2013, Nature.

CHAPTER 4.6 – Targeted sterically stabilized liposomal drug delivery

D. Stuart, T. Allen, C. Hansen, 1998 .

Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects.

B. Calabretta, D. Stuart, T. Allen, 2000, Journal of the National Cancer Institute.

A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.

D. Stuart, T. Allen, 2000, Biochimica et biophysica acta.

Inhibition of prenylated KRAS in a lipid environment

Charles A. Wartchow, W. Jahnke, E. Fang, 2017, PloS one.

Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target

K. Aldape, K. Nathanson, Ju-Seog Lee, 2014, Clinical Cancer Research.

Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.

K. Shoemaker, Z. Ni, S. Cowan-Jacob, 2017, Bioorganic & medicinal chemistry letters.

Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors.

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2014, ACS medicinal chemistry letters.

Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.

S. Gambhir, D. Stuart, Jeffrey R. Tseng, 2011, Neoplasia.

CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations

S. Ramurthy, S. Subramanian, P. Amiri, 2006 .

CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

Fernando Salangsang, E. Venetsanakos, D. Stuart, 2006 .

Title: Molecular Pathways: Response and resistance to BRAF and MEK inhibitors in BRAF tumors Running title: Molecular Pathways: Targeting BRAF tumors

D. Stuart, M. Thakur, 2013 .

Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

B. Calabretta, D. Stuart, T. Allen, 2000, Journal of the National Cancer Institute.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

R. Mosher, W. Sellers, P. Finan, 2010, Proceedings of the National Academy of Sciences.

Targeted delivery of antisense oligonucleotides in cancer.

D. Stuart, T. Allen, F. Pastorino, 2001, Journal of controlled release : official journal of the Controlled Release Society.

Abstract 2337: Efficacy of the RAF/PI3Kα/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600Ecolorectal tumor models.

G. Caponigro, Z. Cao, D. Stuart, 2013 .

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

G. Caponigro, Nanxin Li, Edward G. Lorenzana, 2012 .

RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

D. Ruddy, C. Voliva, Alyson K. Freeman, 2021, Molecular Cancer Research.

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

R. Dummer, P. Nuciforo, Paul D. Smith, 2011, Pigment cell & melanoma research.

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2015, ACS medicinal chemistry letters.

Discovery of RAF 265 : A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2015 .

High efficiency entrapment of antisense oligonucleotides in liposomes.

D. Stuart, T. Allen, S. Semple, 2004, Methods in enzymology.

Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

Isaiah Norton, Nathalie Y. R. Agar, Sandro Santagata, 2013, Scientific Reports.

Linking somatic genetic alterations in cancer to therapeutics.

William R Sellers, W. Sellers, D. Stuart, 2009, Current opinion in cell biology.

In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling

Joshua M. Korn, W. Sellers, J. Korn, 2019, bioRxiv.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

B. Taylor, M. Barbacid, G. Caponigro, 2018, Cancer discovery.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

B. Weisburd, F. McCormick, M. Holderfield, 2014, Cancer research.

Molecular Pathways Molecular Pathways : Response and Resistance to BRAF and MEK Inhibitors in BRAFV 600 E Tumors

D. Stuart, M. Thakur, 2014 .

The evolution of melanoma resistance reveals therapeutic opportunities.

D. Stuart, M. Das Thakur, 2013, Cancer research.

inhibitors in BRAFV 600 E tumors Running title : Molecular Pathways : Targeting BRAFV 600 E tumors

D. Stuart, M. Thakur, 2013 .

Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors

S. Levy, J. Sosman, R. Splittgerber, 2012 .

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma

J. Engelman, D. Ruddy, Alyson K. Freeman, 2018, Molecular Cancer Research.

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

S. Levy, J. Sosman, R. Splittgerber, 2012, Clinical Cancer Research.

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors

M. Holderfield, D. Stuart, T. Nagel, 2014, British Journal of Cancer.

Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer

W. Sellers, D. Stuart, 2013, Nature Medicine.

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

P. Hammerman, G. Caponigro, F. Mapa, 2020, Clinical Cancer Research.

Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors

D. Stuart, M. Thakur, 2013, Clinical Cancer Research.

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts

D. Ruddy, J. Williams, D. Stuart, 2019, Molecular Cancer Therapeutics.

Next-Generation Strategies to Target RAF

D. Stuart, 2017 .

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.

F. McCormick, M. Holderfield, D. Stuart, 2013, Cancer cell.

The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

W. Sellers, Guoying Yu, M. Jensen, 2012, Molecular Cancer Therapeutics.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

W. Sellers, M. P. Dillon, Y. Mishina, 2020, Journal of medicinal chemistry.

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.

A. Fanidi, Yu Ding, B. Appleton, 2016, Journal of medicinal chemistry.

Cancer Cell Inhibitory Autophosphorylation of RAF Kinase in vitro and in cells

F. McCormick, M. Holderfield, D. Stuart, 2013 .

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

V. Sondak, K. Flaherty, J. Kirkwood, 2015, Cancer discovery.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf

Wei Zhang, Edward G. Lorenzana, Fernando Salangsang, 2006 .

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Joshua M. Korn, W. Sellers, F. Shen, 2018, Cancer research.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

R. Sullivan, M. Hidalgo, G. Caponigro, 2017, Clinical Cancer Research.

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

P. Hammerman, G. Caponigro, S. Silver, 2019, Molecular Cancer Therapeutics.

Preclinical Development The Novel Oral Hsp 90 Inhibitor NVP-HSP 990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

W. Sellers, Guoying Yu, M. Jensen, 2012 .

THE NOVEL ORAL HSP 90 INHIBITOR NVP-HSP 990 EXHIBITS POTENT AND BROAD-SPECTRUM ANTI-TUMOR ACTIVITIES IN VITRO AND IN VIVO

W. Sellers, Guoying Yu, M. Jensen, 2011 .

Abstract LB-114: RAF inhibitor LXH254 effectively inhibits B-and-CRAF, but not ARAF

G. Caponigro, D. Stuart, Yun Feng, 2019, Experimental and Molecular Therapeutics.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

W. Sellers, R. Dummer, Fernando Salangsang, 2013, Nature.

The evolution of melanoma resistance reveals therapeutic opportunities.

D. Stuart, M. Das Thakur, 2013, Cancer research.

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

G. Kryukov, L. Buckbinder, E. Jackson, 2023, Cancer discovery.